Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.
Results from up to eight stages of mouse or human retina development highlight the importance of histone modifications and other epigenetic shifts during differentiation.
Expression profiles of 1,900 B-cell acute lymphoblastic leukemia cases point to the presence of a subtype marked by rearrangements in transcription factor DUX4.
The partners will exchange all information they have on genetic mutations leading to cancer with an eye toward accelerating research and drug discovery efforts.
